2007-06-0608-001.

txt 6/8/2007

FOR IMMEDIATE RELEASE:

Crescent Diagnostics Announces Positive Clinical Results for its Novel Bone
Quality Test, BQT(TM)
Study results provide further evidence of the potential of BQT(TM) as a test
for osteoporosis
LONDON, UK - June 8, 2007 (SEND2PRESS NEWSWIRE) -- Crescent Diagnostics Ltd
("Crescent"), today announced the publication of a recent study demonstrating
the potential of the Bone Quality Test, BQT(TM) to diagnose osteoporosis. More
women at risk can be screened with an accurate, simple to use test which does
not require a hospital visit.
*(LOGO: Send2Press.com/mediaroom/07-0608-Crescent_72dpi.jpg)

Crescent is conducting multiple clinical studies to investigate the ability of

the BQT(TM) to detect osteoporosis and expand the screening of women at risk.
The most recent published study carried out at the University of Limerick,
Ireland compared the potential of the BQT(TM) to identify patients at risk of
fracture with DXA, the current reference standard that measures bone mineral
density ("BMD"). The study compared the fingernail clippings of 169 patients,
39 with a history of fracture and the remainder in a control group with no
fracture history. The lower disulphide content in nails obtained from patients
with a history of fracture was statistically significantly lower than in
patients without a history of fracture (p=0.025). 26 out of 39 subjects (67%)
with a history of fracture recorded values below the cut-off value for
disulphide content of the nail as measured by Raman spectroscopy.

Commenting on these findings Ernest Poku, Chief Executive Officer of Crescent

said, "We are pleased that these preliminary results confirm the earlier
clinical findings and show the potential of the BQT to aid the identification
of individuals at risk of osteoporosis at a much lower cost than current
tests."
Crescent recently began recruiting patients for FRAN, a large multi-centre
trial in the UK and Ireland. This study aims to demonstrate the potential of
the BQT(TM) to evaluate fracture risk in hundreds of post-menopausal women.
The results are expected in early 2008.
Mr. Poku explained that Crescent "now plans to enter into dialogue with
regulatory agencies to determine the optimum route to market approval for the
test." The company is planning to complete a Series A funding round in early
2008 to provide the funding to complete the BQT(TM) regulatory process.
Crescent, founded in 2004, is a development stage diagnostic company focused
on advancing its BQT(TM). Low cost accurate alternatives to DEXA are needed to
enable wider osteoporosis screening.

About Crescent Diagnostics Ltd

Crescent Diagnostics is redefining the diagnosis and treatment of osteoporosis

by developing the BQT(TM), a novel test which assesses human fingernail
structure as a surrogate marker for bone structure. A BQT(TM) Point of Care
test could be simple and accurate enough to enable wider population screening,
addressing a market exceeding $700m. Crescent Diagnostics has offices in
Limerick, Ireland and London, UK. For more information visit
http://www.crescentds.com

About Bone Quality Test, BQT(TM)

The Bone Quality Test is a Raman spectroscopy analysis performed on the nail
in-situ or on a nail clipping. The results are highly repeatable and the test
can be delivered at the point of care cost effectively. The BQT(TM) addresses
the need for more accurate osteoporosis testing to reduce fractures in the

1
2007-06-0608-001.txt 6/8/2007

community which costs billions of dollars worldwide annually.

Journal Reference
Towler et al - Journal of Materials Science: Materials in Medicine. J Mater
Sci: Mater Med (2007) 18:759-763. Published as epub ahead of print 30 November
2006

Send2Press(R) is the originating wire service for this story -

www.Send2Press.com
NEWS SOURCE: Crescent Diagnostics, Ltd

# # #

/END/

MEDIA CONTACT(S):
[ not for publication online or in print ]

Ernest Poku, CEO

Crescent Diagnostics, Ltd
+ 44 20 7463 2096
info @ crescentds.com

.........
Text provided by news source who is solely responsible for accuracy of
content.
.........
This news story from Send2Press Newswire may be redistributed and re-posted in
part or in whole by members of the media. Copr. (c) Send2Press, a unit of
Neotrope(R). For news aggregation sites, blogs, and bureaus, you must retain
Send2Press as the original wire service source. Do not stream graphics from
our server.
.........
The original version of this release was issued on behalf of the above
organization (the "news source"), by Send2Press(R) Newswire, a unit of
Neotrope(R). http://www.Send2Press.com
.........
Get our full-text news via RSS: http://www.send2press.com/RSS2/rss.xml
.........
Story Permalink: http://www.Send2Press.com/mediadrome/2007-06-0608-001.txt
June 2007 // Press Release / Snd